EXHIBIT 10.1
Execution Version
CONFIDENTIAL PROVISIONS
REDACTED
COLLABORATION
AGREEMENT
THIS COLLABORATION
AGREEMENT (the “
Agreement ”) is entered into as of September 12,
2005 (the “ Effective Date ”) by and between
Protein Design Labs, Inc., a Delaware corporation having its
offices at 34801 Campus Drive, Fremont, California 94555 (“
PDL ”), and Biogen Idec MA Inc., a Massachusetts
corporation having offices at 14 Cambridge Center, Cambridge,
Massachusetts 02142 (“ Biogen Idec ”). PDL and
Biogen Idec may each be referred to in this Agreement individually
as a “ Party ” and collectively as the “
Parties .”
RECITALS
WHEREAS , PDL possesses worldwide rights to develop,
manufacture, market, and sell certain proprietary antibodies
directed at certain antigens (such antigens defined below as
“Collaboration Targets”) and;
WHEREAS, PDL has research and development programs for
such antibodies as well and for certain compounds relating to the
Collaboration Targets; and
WHEREAS , Biogen Idec and PDL wish to collaborate in the
research, development, manufacturing and commercialization of
products for the Collaboration Targets, including such antibodies
and compounds, under the terms and conditions set forth
below.
NOW THEREFORE
, in consideration of the foregoing
premises and the mutual covenants contained herein, the Parties,
intending to be legally bound, agree as follows:
ARTICLE 1
DEFINITIONS
The following capitalized terms,
whether used in the singular or the plural, shall have the
following meanings as used in this Agreement unless otherwise
specifically indicated:
*Certain information on this
page has been omitted and filed separately with the
commission. Confidential treatment has been requested with respect
to the omitted portions.
